GI CANCERS

Latest News

Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC
Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC

October 28th 2024

Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.

Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer
Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer

October 18th 2024

FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer
FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer

October 18th 2024

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer
Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

October 10th 2024

Namodenoson Earns FDA Orphan Drug Designation in Pancreatic Cancer
Namodenoson Earns FDA Orphan Drug Designation in Pancreatic Cancer

October 9th 2024

More News